BenevolentAI (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, announces that trading in its shares is expected to begin today, following completion of the business combination of BenevolentAI Limited with Odyssey Acquisition S.A. (“Odyssey”) on 22 April 2022 (the “Business Combination”). Highlights The combined company now operates under the name BenevolentAI and will trade on Euronext Amsterdam under the ticker symbol BAI Gross proceeds from the Business Combination of €225 million will put BenevolentAI in...